Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...

The antihistamine didn’t control the eczema. Sidbury R, Davis DM, et al. “Guidelines of care for the management of atopic dermatitis, Part 3: Guidelines of care for the management and treatment of ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

to twice-daily azelastine (an intranasal antihistamine), fluticasone propionate, the combination of the two, or placebo for 2 weeks during the allergy season; all treatments were administered as ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

CRAIG T. KOJIMA / NOV. 6 The judge instructed jurors Wednesday that they were allowed to find babysitter Dixie Denise Villa ...

The state and the defense presented their final witnesses Tuesday in the manslaughter trial of Dixie Denise Villa, accused of giving a fatal dose of diphenhydramine, the antihistamine found in ...